Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Nicholas Butowski
- Target Recruit Count
- 70
- Registration Number
- NCT06504381
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06475235
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 62
- Registration Number
- NCT06450041
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06448286
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
STARLITE for Unresectable High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 24
- Registration Number
- NCT06428045
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 200
- Registration Number
- NCT06419946
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT06413706
- Locations
- 🇧🇪
Centre Hospitalier Regional de la Citadelle, Liege, Belgium
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Triapine in Combination with Temozolomide for the Treatment of Patients with Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT06410248
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.